Skip to main content

Table 4 Cox proportional hazards model with CTC KIN

From: Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients

  PFS OS
Hazard ratio 95% CI P Hazard ratio 95% CI P
CTC KIN
 CTCBL- to CTC1C- 1.00    1.00   
 CTCBL+ to CTC1C- 1.01 0.62–1.64 0.981 1.68 0.85–3.32 0.135
 CTCBL+ to CTC1C+ 2.17 1.39–3.37 < 0.001 5.58 3.06–10.15 < 0.001
 CTCBL- to CTC1C+ 2.17 0.91–5.14 0.079 2.56 0.76–8.00 0.134
Age at inclusion
 Per year 0.99 0.98–1.00 0.333 0.99 0.97–1.01 0.284
Number of metastatic sites
 One site 1.00    1.00   
 Multiple sites 0.94 0.98–1.01 0.832 0.59 0.24–1.48 0.260
Site of metastasis
 Bone 1.00    1.00   
 Visceral/local 1.10 0.59–2.04 0.768 2.12 0.82–5.49 0.124
 Both 1.27 0.68–2.37 0.449 3.35 1.27–8.82 0.014
Line of therapy
 1 1.00    1.00   
 2 1.66 1.00–2.75 0.049 2.01 1.02–3.99 0.045
 ≥ 3 2.49 1.58–3.94 < 0.001 2.49 1.32–4.65 0.004
Molecular Subtypes
 HR+/HER2- 1.00    1.00   
 HER2+ 1.34 0.81–2.19 0.252 1.37 0.64–2.91 0.418
 TNBC 2.58 1.53–4.35 < 0.001 3.92 2.11–7.30 < 0.001
  1. Bold P values indicate statistical significance.
  2. HR, hormone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple negative breast cancer.